▟ Vinebot intrinsic value, daily

← back

CTVA Corteva

materials · valued with opus low conviction · deep-dived 2026-10-12

STRONG BUY
Intrinsic value$33.91
Price (at call)$13.24
Margin of safety +156.1%
vs market (rating basis) +223.4%

Durable seed franchise inside a commoditizing chemicals shell; first check whether the quoted price is real.

The story

Corteva is a mature, global agricultural inputs company, roughly 60% seed (Pioneer germplasm and trait licensing, a durable franchise) and 40% crop protection (facing generic Chinese competition and pricing pressure). It is mid-way through a self-help margin story: royalty-neutral transition to its own Enlist/Vorceed traits, biologicals and cost cuts. A planned separation of seed and crop protection could expose the seed franchise's value, though the consolidated whole remains a slow-growth, cyclical business.

Growth of about 3.5% reflects flat 5-year revenue with seed pricing power offset by crop protection deflation. Margin rises from 10.9% to 14% (not the 16% or more management targets) as royalty savings and cost programs land but crop protection stays commoditized. Sales-to-capital is set at 0.9 rather than the reported 0.67 because the reported figure is depressed by merger goodwill and incremental reinvestment is lighter. Beta sits just below the 1.1 materials anchor because farm demand is defensive. Confidence is low because the inputs look inconsistent: a $13.24 price and 667M shares give an $8.8B market cap against $1.16B of net income (about 7.6x P/E), which does not match how CTVA has historically traded. This may be a split, spin-off or data error, so the price should be verified before acting on any margin of safety.

Value drivers

Revenue growth (Y1)3.5%
Terminal growth3.0%
Forecast horizon8y
Target operating margin14.0%
Years to target margin5
Sales-to-capital0.90
Beta0.95
Failure probability1.0%
Cost of capital (WACC)8.5%
Terminal WACC8.6%

Valuation bridge

PV of explicit FCFF6.76B
PV of terminal value14.39B
Equity value22.62B
÷ shares → per share$33.91

Projected free cash flow to the firm

YrRevenueGrowthMarginNOPATReinvestFCFFPV
1 18.52B 3.5% 11.5% 1.52B 695.68M 821.01M 757.01M
2 19.15B 3.4% 12.1% 1.65B 705.34M 949.25M 807.02M
3 19.79B 3.4% 12.7% 1.80B 714.32M 1.08B 850.20M
4 20.44B 3.3% 13.4% 1.95B 722.59M 1.23B 886.94M
5 21.10B 3.2% 14.0% 2.11B 730.11M 1.38B 917.63M
6 21.76B 3.1% 14.0% 2.17B 736.83M 1.44B 882.65M
7 22.43B 3.1% 14.0% 2.24B 742.72M 1.50B 848.33M
8 23.10B 3.0% 14.0% 2.31B 747.73M 1.56B 814.69M

Key risks

  • Generic crop-protection pricing pressure from Chinese producers compresses margins
  • Execution and stranded costs from the seed/crop-protection separation
  • Farm income downturn, weather and commodity price cycles reduce input demand

Catalysts

  • Completion of the separation unlocking a seed-pure-play valuation
  • Royalty cost savings from the shift to proprietary traits driving margin expansion toward 14-16%

⚠ Extreme gap to market price — large, heavily-covered stocks are rarely mispriced this much; the gap likely embeds disruption, decline, or balance-sheet risk the model underweights. Treat as a flag to investigate, not a verdict.

History

DatePriceIntrinsicMoSRating
2026-10-12$13.24 $33.91 +156.1% STRONG BUY
2026-09-09$85.90 $27.13 -68.4% SELL
2026-08-06$78.67 $35.95 -54.3% HOLD
2026-07-02$83.54 $32.26 -61.4% SELL
2026-06-23$79.11 $32.12 -59.4% SELL